Free Newsletter
FDA to review GSK's rotavirus vaccine
Free newsletter via e-mail
Tools
The feds have agreed to consider allowing GlaxoSmithKline to sell its rotavirus vaccine, Rotarix, in the U.S. Already licensed in nearly 100 countries, Rotarix is designed to protect children from the virus, which can cause severe diarrhea and dehydration. It would compete against RotaTeq, Merck's product, which is already approved for sale. Several medical societies and the U.S. government recommend that all infants receive rotavirus vaccinations.
- see this release
- here's the report from the Triangle Business Journal
- and here's the AP report
More stories about GlaxoSmithKline
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
